KRAS and colorectal cancer: To test this concept further, we utilised two cell lines with basally high mTORC1 signalling (Figure 6): the NCI-H460 large cell lung cancer cell line which has PI3KCA, CDKN2A, STK11 and KRAS mutations [39] and the HCT116 colorectal cancer cell line, which contains an activating RAS mutation [40] and PIK3CA mutation [41].